MyoKardia, Inc. (NASDAQ:MYOK) had its price target hoisted by equities researchers at Cowen and Company from $28.00 to $56.00 in a note issued to investors on Monday. Cowen and Company’s target price indicates a potential upside of 78.06% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. ValuEngine raised shares of MyoKardia from a “sell” rating to a “hold” rating in a research note on Monday. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $48.00 target price (up from $31.00) on shares of MyoKardia in a research note on Monday. BidaskClub raised shares of MyoKardia from a “buy” rating to a “strong-buy” rating in a research note on Saturday. TheStreet raised shares of MyoKardia from a “d+” rating to a “c” rating in a research note on Thursday, July 6th. Finally, Zacks Investment Research downgraded shares of MyoKardia from a “hold” rating to a “sell” rating in a research note on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. MyoKardia has an average rating of “Buy” and an average target price of $35.00.

MyoKardia (NASDAQ MYOK) traded up 83.38% on Monday, hitting $31.45. 8,757,035 shares of the stock traded hands. MyoKardia has a 12-month low of $10.55 and a 12-month high of $32.30. The stock’s market cap is $989.26 million. The stock has a 50-day moving average price of $14.02 and a 200 day moving average price of $13.13.

MyoKardia (NASDAQ:MYOK) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.04. MyoKardia had a negative return on equity of 15.27% and a negative net margin of 39.44%. The company had revenue of $5.60 million during the quarter, compared to the consensus estimate of $6.73 million. During the same period in the prior year, the firm posted ($0.37) earnings per share. The company’s revenue was up 60.0% on a year-over-year basis. On average, equities analysts expect that MyoKardia will post ($1.54) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international trademark and copyright law. The legal version of this article can be read at https://www.dailypolitical.com/2017/08/07/cowen-and-company-boosts-myokardia-inc-nasdaqmyok-price-target-to-56-00.html.

In other news, CEO Anastasios Gianakakos sold 4,300 shares of MyoKardia stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $16.62, for a total transaction of $71,466.00. Following the completion of the sale, the chief executive officer now owns 512,463 shares in the company, valued at approximately $8,517,135.06. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 46.10% of the stock is owned by insiders.

Several large investors have recently modified their holdings of the company. Wellington Management Group LLP boosted its stake in shares of MyoKardia by 12.5% in the first quarter. Wellington Management Group LLP now owns 3,154,734 shares of the biotechnology company’s stock valued at $41,485,000 after buying an additional 349,768 shares in the last quarter. MARSHALL WACE ASIA Ltd acquired a new stake in shares of MyoKardia during the first quarter valued at approximately $1,577,000. Marshall Wace North America L.P. acquired a new stake in shares of MyoKardia during the first quarter valued at approximately $1,577,000. Point72 Asset Management L.P. acquired a new stake in shares of MyoKardia during the first quarter valued at approximately $1,546,000. Finally, TFS Capital LLC acquired a new stake in shares of MyoKardia during the first quarter valued at approximately $934,000. Institutional investors own 47.74% of the company’s stock.

About MyoKardia

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.